The estimated Net Worth of David W. Boyer is at least $5.09 Million dollars as of 13 February 2024. Mr. Boyer owns over 1,811 units of Neurocrine Biosciences stock worth over $594,596 and over the last 3 years he sold NBIX stock worth over $4,492,663. In addition, he makes $0 as Chief Corporate Affairs Officer at Neurocrine Biosciences.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr. Boyer NBIX stock SEC Form 4 insiders trading
David has made over 11 trades of the Neurocrine Biosciences stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 1,811 units of NBIX stock worth $240,990 on 13 February 2024.
The largest trade he's ever made was selling 25,238 units of Neurocrine Biosciences stock on 6 February 2023 worth over $2,586,643. On average, David trades about 3,456 units every 61 days since 2022. As of 13 February 2024 he still owns at least 4,895 units of Neurocrine Biosciences stock.
You can see the complete history of Mr. Boyer stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
David Boyer biography
David W. Boyer serves as Chief Corporate Affairs Officer of the Company. He was appointed Chief Corporate Affairs Officer in September 2019 and is responsible for patient advocacy and engagement, corporate communications, government relations, and public policy at Neurocrine Biosciences. Mr. Boyer brings nearly 20 years of experience in public affairs, specializing in the life sciences and biopharmaceutical sectors. He joins Neurocrine Biosciences from nine years at BGR Group, where he served as a Principal and the Head of the Health & Lifesciences Practice, leading the firm’s healthcare advocacy, policy and strategy development, and strategic consulting team. During his tenure at BGR Group, Mr. Boyer led public policy, advocacy, and strategic communications initiatives for a wide range of healthcare clients. Prior to joining BGR Group, Mr. Boyer served as Special Assistant to the President for Legislative Affairs under President George W. Bush, Assistant Commissioner for Legislation at the U.S. Food and Drug Administration, and Special Assistant to the Secretary at the U.S. Department of Health and Human Services. In addition to his public service, Mr. Boyer held senior advocacy positions at the Biotechnology Innovation Organization (BIO) and the Pharmaceutical Research and Manufacturers of America (PhRMA). Mr. Boyer holds a B.A. in Government from Georgetown University.
How old is David Boyer?
David Boyer is 41, he's been the Chief Corporate Affairs Officer of Neurocrine Biosciences since 2019. There are 22 older and 1 younger executives at Neurocrine Biosciences. The oldest executive at Neurocrine Biosciences, Inc. is William Rastetter, 72, who is the Independent Chairman of the Board.
What's David Boyer's mailing address?
David's mailing address filed with the SEC is 12780, El Camino Real, San Diego, San Diego County, California, 92014, United States.
Insiders trading at Neurocrine Biosciences
Over the last 22 years, insiders at Neurocrine Biosciences have traded over $159,913,426 worth of Neurocrine Biosciences stock and bought 103,400 units worth $589,660 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog..., and Richard F Pops. On average, Neurocrine Biosciences executives and independent directors trade stock every 8 days with the average trade being worth of $1,567,813. The most recent stock trade was executed by William H Rastetter on 15 August 2024, trading 14,250 units of NBIX stock currently worth $2,090,333.
What does Neurocrine Biosciences do?
neurocrine biosciences, inc of san diego is a product based biopharmaceutical company focusing on the development and commercialization of innovative pharmaceutical products to treat unmet medical needs. the company's research and development efforts are focused on neurological and endocrine diseases and disorders. our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome, anxiety, depression, pain, diabetes, insomnia, and other neurological and endocrine related diseases and disorders
What does Neurocrine Biosciences's logo look like?
Complete history of Mr. Boyer stock trades at Neurocrine Biosciences
Neurocrine Biosciences executives and stock owners
Neurocrine Biosciences executives and other stock owners filed with the SEC include:
-
Kevin Gorman,
Chief Executive Officer, Director -
Matthew Abernethy,
Chief Financial Officer -
Eric Benevich,
Chief Commercial Officer -
Eiry Roberts,
Chief Medical Officer -
Haig Bozigian,
Chief Development Officer -
Kyle Gano,
Chief Business Development and Strategy Officer -
Dimitri Grigoriadis,
Chief Research Officer -
Dr. Kevin C. Gorman Ph.D.,
CEO & Director -
Dr. Eiry Wyn Roberts,
Chief Medical Officer -
Leslie Norwalk,
Independent Director -
Matthew C. Abernethy,
Chief Financial Officer -
Eric S. Benevich,
Chief Commercial Officer -
Kyle W. Gano,
Chief Bus. Devel. and Strategy Officer -
William Rastetter,
Independent Chairman of the Board -
Stephen Sherwin,
Independent Director -
Richard Pops,
Independent Director -
George Morrow,
Independent Director -
Gary Lyons,
Independent Director -
Todd Tushla,
Investor Relations -
Julie Cooke,
Chief Human Resource Officer -
Shalini Sharp,
Independent Director -
Darin Lippoldt,
Chief Legal Officer and Corporate Secretary -
Malcolm Lloyd-Smith,
Chief Regulatory Officer -
David Boyer,
Chief Corporate Affairs Officer -
Julie S. Cooke,
Chief HR Officer -
Darin M. Lippoldt,
Chief Legal Officer & Corp. Sec. -
Jane Sorensen,
Head of Investor Relations -
Dr. Jude Onyia Ph.D.,
Chief Scientific Officer -
Dr. Dimitri E. Grigoriadis,
Chief Research Officer -
Matt Abernethy,
Chief Financial Officer -
Corinne H Nevinny,
Director -
Christopher Flint O Brien,
Sr. VP & Chief Medical Officer -
Joseph A Mollica,
Director -
David Alexandre C Gros,
President & COO -
Alfred Sandrock,
Director -
Christine A Poon,
Director -
Wylie W Vale,
Director -
Timothy Coughlin,
VP and Chief Financial Officer -
Jensen Margaret E Valeur,
Senior VP and General Counsel -
Partners L P/Ilbiotechnolog...,
-
Johanna Mercier,
Director -
Partners L P/Ilbiotechnolog...,
-
Partners L P/Ilbiotechnolog...,
-
Henry Pan,
Executive VP and CMO -
Wendall Wierenga,
EVP, Research & Development -
Richard J Ranieri,
Sr. VP, Human Resources -
Thomas Mitchell W,
Director -
Ingrid Delaet,
Chief Regulatory Officer -
Paul W Hawran,
Executive VP and CFO -
Paul J Conlon,
Vice President Research (Biol) -
Lawrence Steinman,
Director -
John Saunders,
Vice President Research (Chem) -
Robert J Little,
SVP, Commercial Operations -
D Bruce Campbell,
Senior Vice President -
Jude Onyia,
Chief Scientific Officer